FPR A14FPR agonist CAS# 329691-12-5 |
- Calyculin A
Catalog No.:BCC2457
CAS No.:101932-71-2
- Fumonisin B1
Catalog No.:BCC2461
CAS No.:116355-83-0
- Calcineurin Autoinhibitory Peptide
Catalog No.:BCC2456
CAS No.:148067-21-4
- DL-AP3
Catalog No.:BCC2459
CAS No.:20263-06-3
- Ceramide
Catalog No.:BCC2458
CAS No.:3102-57-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 329691-12-5 | SDF | Download SDF |
| PubChem ID | 5503194 | Appearance | Powder |
| Formula | C23H20N2O5 | M.Wt | 404.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | N-[(Z)-(3-methoxy-4-phenylmethoxyphenyl)methylideneamino]-1,3-benzodioxole-5-carboxamide | ||
| SMILES | COC1=C(C=CC(=C1)C=NNC(=O)C2=CC3=C(C=C2)OCO3)OCC4=CC=CC=C4 | ||
| Standard InChIKey | ULOKADSYVZOTTL-CFRMEGHHSA-N | ||
| Standard InChI | InChI=1S/C23H20N2O5/c1-27-21-11-17(7-9-19(21)28-14-16-5-3-2-4-6-16)13-24-25-23(26)18-8-10-20-22(12-18)30-15-29-20/h2-13H,14-15H2,1H3,(H,25,26)/b24-13- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Formyl peptide receptor (FPR) agonist that potently activates neutrophils in vitro (EC50 values are 42 and 630 nM for neutrophil chemotaxis and Ca2+ mobilization respectively). |
FPR A14 Dilution Calculator
FPR A14 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4727 mL | 12.3634 mL | 24.7268 mL | 49.4535 mL | 61.8169 mL |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL | 9.8907 mL | 12.3634 mL |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4727 mL | 4.9454 mL | 6.1817 mL |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL | 0.9891 mL | 1.2363 mL |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.4945 mL | 0.6182 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 7-O-Methylaloeresin A
Catalog No.:BCN2849
CAS No.:329361-25-3
- Sanggenol L
Catalog No.:BCN3692
CAS No.:329319-20-2
- Boc-His(Trt)-OH
Catalog No.:BCC3403
CAS No.:32926-43-5
- Quetiapine hydroxy impurity
Catalog No.:BCN5340
CAS No.:329216-67-3
- SANT-2
Catalog No.:BCC3937
CAS No.:329196-48-7
- Withanolide A
Catalog No.:BCN8010
CAS No.:32911-62-9
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- DL-Adrenaline
Catalog No.:BCC4318
CAS No.:329-65-7
- Norepinephrine hydrochloride
Catalog No.:BCC5133
CAS No.:329-56-6
- 4E1RCat
Catalog No.:BCC5338
CAS No.:328998-25-0
- C646
Catalog No.:BCC4546
CAS No.:328968-36-1
- pep2-SVKI
Catalog No.:BCC5784
CAS No.:328944-75-8
- Pinoresinol diacetate
Catalog No.:BCN5250
CAS No.:32971-25-8
- 2-Acetyl-3-ethylpyrazine
Catalog No.:BCC8512
CAS No.:32974-92-8
- Cinaciguat
Catalog No.:BCC1484
CAS No.:329773-35-5
- Methyl (2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate
Catalog No.:BCN8520
CAS No.:32981-85-4
- 10-Deacetylbaccatin III
Catalog No.:BCN5251
CAS No.:32981-86-5
- Tobramycin
Catalog No.:BCC4739
CAS No.:32986-56-4
- Viomycin
Catalog No.:BCC3930
CAS No.:32988-50-4
- TTP 22
Catalog No.:BCC2017
CAS No.:329907-28-0
- 3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid
Catalog No.:BCN1458
CAS No.:329975-47-5
- Nicarbazin
Catalog No.:BCC9101
CAS No.:330-95-0
- Kumatakenin
Catalog No.:BCN5252
CAS No.:3301-49-3
- ent-16beta,17-Dihydroxy-19-kauranoic acid
Catalog No.:BCN1457
CAS No.:3301-61-9
High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.[Pubmed:17229869]
Mol Pharmacol. 2007 Apr;71(4):1061-74.
We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca(2+) mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4'-benzyloxy-3'-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca(2+) mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5-carboxylic acid 3'-bromo-5'-ethoxy-4'-hydroxybenzylidene-hydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca(2+) mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.
